JP2010508857A - パパイヤモザイクウイルスに基づく免疫原性の親和性で複合体化された抗原系及びその使用 - Google Patents

パパイヤモザイクウイルスに基づく免疫原性の親和性で複合体化された抗原系及びその使用 Download PDF

Info

Publication number
JP2010508857A
JP2010508857A JP2009536566A JP2009536566A JP2010508857A JP 2010508857 A JP2010508857 A JP 2010508857A JP 2009536566 A JP2009536566 A JP 2009536566A JP 2009536566 A JP2009536566 A JP 2009536566A JP 2010508857 A JP2010508857 A JP 2010508857A
Authority
JP
Japan
Prior art keywords
papmv
affinity
antigen
animal
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009536566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508857A5 (enExample
Inventor
ルクレール、デニス
Original Assignee
フォリア バイオテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォリア バイオテック インコーポレイテッド filed Critical フォリア バイオテック インコーポレイテッド
Publication of JP2010508857A publication Critical patent/JP2010508857A/ja
Publication of JP2010508857A5 publication Critical patent/JP2010508857A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009536566A 2006-11-15 2007-10-25 パパイヤモザイクウイルスに基づく免疫原性の親和性で複合体化された抗原系及びその使用 Pending JP2010508857A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86599706P 2006-11-15 2006-11-15
US88687307P 2007-01-26 2007-01-26
PCT/CA2007/001904 WO2008058369A1 (en) 2006-11-15 2007-10-25 Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof

Publications (2)

Publication Number Publication Date
JP2010508857A true JP2010508857A (ja) 2010-03-25
JP2010508857A5 JP2010508857A5 (enExample) 2010-12-16

Family

ID=39401271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536566A Pending JP2010508857A (ja) 2006-11-15 2007-10-25 パパイヤモザイクウイルスに基づく免疫原性の親和性で複合体化された抗原系及びその使用

Country Status (5)

Country Link
US (1) US20100047264A1 (enExample)
EP (1) EP2078086A4 (enExample)
JP (1) JP2010508857A (enExample)
CA (1) CA2669345A1 (enExample)
WO (1) WO2008058369A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
JP2014514350A (ja) * 2011-05-13 2014-06-19 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルス組成物および自然免疫応答刺激のためのその使用
JP2015514097A (ja) * 2012-04-02 2015-05-18 フォリア バイオテック インコーポレイテッド 組換えパパイヤモザイクウイルスコートタンパク質およびインフルエンザワクチンにおけるその使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
EP2082042A4 (en) * 2007-01-26 2010-08-18 Folia Biotech Inc VACCINE VACCINE FROM PAPAYA MOSAIC AGAINST SALMONELLA TYPHI AND OTHER ENTEROBACTERIAL PATHOGENS
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
CA2763795A1 (en) * 2010-10-14 2012-03-20 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
WO2012078069A1 (en) 2010-12-09 2012-06-14 Iosif Grigorievich Atabekov Spherical nano- and microparticles derived from plant viruses for the display of foreign proteins or epitopes
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508748A (ja) * 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
JP2006504644A (ja) * 2002-07-05 2006-02-09 デニス レクレルク アジュバントウィルス粒子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198401A (en) * 1987-01-30 1993-03-30 Exxon Chemical Patents Inc. Ionic metallocene catalyst compositions
GB9607899D0 (en) 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
DK1135408T3 (da) 1998-12-04 2012-01-23 Biogen Idec Inc HBV-kerneantigenpartikler med multipelle immunogene komponenter, som er bundne via peptidligander
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
ATE418997T1 (de) 2000-07-06 2009-01-15 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508748A (ja) * 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
JP2006504644A (ja) * 2002-07-05 2006-02-09 デニス レクレルク アジュバントウィルス粒子

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012056460; 金光修著: 「抗体工学入門」 , 1994, ｐ．６０-６７, 株式会社　地人書館 *
JPN6012056462; Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１２４, 2007, ｐ．１８６-１９７ *
JPN6012056466; Ｖｉｒｏｌｏｇｙ Ｖｏｌ．３６３, 2007, ｐ．５９-６８ *
JPN6012056470; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．８１，　Ｎｏ．３, 2007, ｐ．１３１９-１３２６ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
JP2014514350A (ja) * 2011-05-13 2014-06-19 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルス組成物および自然免疫応答刺激のためのその使用
US9833504B2 (en) 2011-05-13 2017-12-05 Folia Biotech Inc. Virus-like particles and process for preparing same
JP2015514097A (ja) * 2012-04-02 2015-05-18 フォリア バイオテック インコーポレイテッド 組換えパパイヤモザイクウイルスコートタンパク質およびインフルエンザワクチンにおけるその使用

Also Published As

Publication number Publication date
CA2669345A1 (en) 2008-05-22
WO2008058369A1 (en) 2008-05-22
EP2078086A1 (en) 2009-07-15
US20100047264A1 (en) 2010-02-25
EP2078086A4 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
US20100047264A1 (en) Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof
US20110206727A1 (en) Multivalent Vaccines Based on Papaya Mosaic Virus and Uses Thereof
JP4087898B2 (ja) 免疫原性に乏しい抗原と合成ペプチド担体との結合体およびそれらからなるワクチン
JP2010516713A (ja) 腸チフス菌および他の腸内細菌病原体に対するパパイアモザイクウィルスベースのワクチン
JP2013234198A (ja) パパイヤモザイクウイルスに基づくインフルエンザ抗原提示系及びそれを含むインフルエンザワクチン
JP2010538619A (ja) Ｍａｌｖａモザイクウイルスおよびウイルス様粒子およびこれらの使用
US9884107B2 (en) Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
US20130280298A1 (en) Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof
JP2022513452A (ja) 融合によって修飾されたｃｍｖのウイルス様粒子
JP2015529677A (ja) ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド
Narayanan et al. Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy
CN101262881A (zh) 通过交叉β结构的佐剂化
US20110189231A1 (en) Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
EP4164681A1 (en) Bacterial immunization using nanoparticle vaccine
JP2018500389A (ja) 効率的な抗体産生のための免疫化に使用される新規なタンパク質構造
US20150056231A1 (en) Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
Zhao Self-Adjuvanted Virus-like Particle for Safe and Highly Immunogenic Vaccination
EA025417B1 (ru) Вакцины с повышенной иммуногенностью и способы их получения
Wagachchi Pilvax: A Novel Peptide Antigen Delivery Strategy for the Generation of Vaccines
Wagachchi Libraries and Learning Services

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130326